Related Experiment Video

Updated: Nov 17, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

Targeting Nrf2 may reverse the drug resistance in ovarian cancer

Danjie Li1, Xiaoling Hong1, Feijie Zhao1

  • 1Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China.

Cancer Cell International
|February 18, 2021
PubMed
Abstract

Insights

Ovarian cancer cells develop chemotherapy resistance by decreasing reactive oxygen species, partly due to the Nrf2 pathway. Inhibiting this pathway may help reverse drug resistance and improve treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Acquired resistance to chemotherapy is a major challenge in ovarian cancer treatment.
  • Decreased mitochondrial reactive oxygen species (ROS) production contributes to chemotherapy resistance in ovarian cancer cells.

Purpose of the Study:

  • To review the role of the Nuclear erythroid-related factor-2 (Nrf2) pathway in chemotherapy resistance in ovarian cancer.
  • To explore the potential of inhibiting the Nrf2 pathway to overcome drug resistance.

Main Methods:

  • Review of existing studies on the Keap1-Nrf2-ARE signaling pathway.
  • Analysis of Nrf2's function in promoting tumor cell growth and drug resistance.

Main Results:

  • The Nrf2 pathway regulates genes involved in oxidative stress defense.
  • Nrf2 activation promotes tumor cell survival and chemotherapy resistance.
  • Inhibition of Nrf2 may reverse acquired resistance to chemotherapy drugs.

Conclusions:

  • Understanding the mechanisms of Nrf2 in drug resistance is crucial.
  • Targeting the Nrf2 pathway holds promise for improving ovarian cancer therapy outcomes.
Keywords:
Drug resistanceNrf2Ovarian cancerReactive oxidative stress

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
16.9K